pharmaceuticals
pharmaceuticals Articles
When pharmaceutical companies lose patent cases on the blockbuster drugs, it usually means that they are at risk of losing billions of dollars in drug sales.
Published:
Last Updated:
In a new report, SunTrust Robinson Humphrey analysts are focused on upcoming catalysts for biotech stocks in their coverage universe.
Published:
Last Updated:
Eli Lilly released a mixed fourth-quarter earnings report and offered full-year guidance before the markets opened on Tuesday.
Published:
Last Updated:
Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) saw its shares rise handily on Monday following positive top-line results from the company’s first-in-human pilot trial. Specifically, the trial is for...
Published:
Last Updated:
Rigel Pharmaceuticals shares saw a solid gain to kick off the week after the company gave an update on one of its clinical programs.
Published:
Last Updated:
Shares of Calithera Biosciences saw a solid gain early on Monday after the company reported a global collaboration and licensing agreement with Incyte.
Published:
Last Updated:
Pulmatrix saw its shares take a sharp downturn on Monday morning after the company announced that it had entered into a definitive agreement with several investors for a direct offering valued up to...
Published:
Last Updated:
AbbVie reported mixed fourth-quarter financial results and offered guidance before the markets opened on Friday.
Published:
Last Updated:
The January 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly down.
Published:
Last Updated:
The health care sector has some of its biggest players reporting later this week, with one pharma giant’s report already out of the way.
Published:
Last Updated:
Ocular Therapeutix, Inc. (NASDAQ: OCUL) saw its shares take a dive on Tuesday after the company announced the pricing of its secondary offering. The company is pricing its 3.57 million shares at $7...
Published:
Last Updated:
It seems that analysts are taking the forefront and making calls on where the biopharma industry is going ahead of action by the Trump administration.
Published:
Last Updated:
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) saw its shares climb on Monday after the company reported positive preliminary results from its mid-stage trial. Specifically the data came from Mirna’s...
Published:
Last Updated:
Credit Suisse sees future earnings growth from Incyte’s pipeline, with epacadostat’s potential as a best-in-class immunotherapy combination agent making the stock an attractive takeout target.
Published:
Last Updated:
BioMarin Pharmaceutical may have missed out on the Trump rally, but it might not be too late to catch a ride on the wave, at least according to one analyst.
Published:
Last Updated: